During one experiment using a murine model, Pal-GHK was suggested to suppress the activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-B) and p38 mitogen-activated protein kinase (MAPK) signaling pathways, both of which are associated with inflammation
Important safety warnings seek urgent medical attention if you experience: Severe or persistent abdominal pain, which may radiate to the back this could indicate pancreatitis , a serious but rare risk associated with GLP-1based therapies as a class [16] [17] Right upper quadrant pain, fever, or jaundice these may suggest gallbladder disease , another class-associated risk Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function Pregnancy and breastfeeding: Use of GLP-1based therapies and related investigational agents is not recommended during pregnancy or breastfeeding
Satake K, Tsukamoto M, Mitani Y et al (2015) Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens
This issue warrants deeper consideration